Most benefit leaders think they’ve done a full cost analysis of GLP-1 drugs. But there’s one critical driver almost no one is accounting for. You haven’t truly modeled GLP-1 costs until you’ve modeled human behavior.
Plan tweaks and rebates won’t fix a demand engine fueled by daily habits. Until you change that, your pharmacy spend is on a treadmill — always moving, never truly reaching a destination.
